See the DrugPatentWatch profile for Onivyde
Onivyde was launched as a new treatment option for pancreatic cancer. It is an albumin-bound formulation of irinotecan, designed to improve drug delivery to tumors.
How does Onivyde work?
Onivyde functions as a topoisomerase I inhibitor. It works by targeting and disrupting DNA replication in cancer cells, ultimately leading to cell death. This formulation is intended to enhance the delivery of irinotecan to the tumor site [1].
What pancreatic cancer is Onivyde approved for?
Onivyde is approved for patients with metastatic pancreatic adenocarcinoma, following disease progression after gemcitabine-based chemotherapy [1].
When was Onivyde approved?
The U.S. Food and Drug Administration (FDA) approved Onivyde on October 24, 2015 [1].
What are the common side effects of Onivyde?
Common side effects reported with Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis [1].
What is the mechanism of action for Onivyde?
Onivyde is an albumin-bound formulation of irinotecan, a prodrug that is converted to its active form, SN-38. SN-38 inhibits topoisomerase I, an enzyme essential for DNA replication and repair, thereby inducing DNA damage and cell death in cancer cells [1].
What is the drug's development and patent status?
The development of Onivyde involved navigating patent landscapes and regulatory approvals. Information on its patent exclusivity and any ongoing patent challenges can be found through resources like DrugPatentWatch.com [2].
How does Onivyde compare to other pancreatic cancer treatments?
Onivyde is indicated for patients who have already progressed on gemcitabine-based chemotherapy. Its efficacy and safety profile are evaluated in the context of this specific patient population, distinguishing it from first-line treatments [1]. DrugPatentWatch.com can provide comparative analyses and market intelligence on various cancer therapies [2].